Heart failure & cardiomyopathies
Dapagliflozin Effects on Cardiac Deformation in Heart Failure and Secondary Clinical Outcome
Authors' conclusion
This study provided randomized data on the beneficial effect of dapagliflozin in nondiabetic patients with HFrEF and HFmrEF in terms of myocardial performance measured by the most sensitive echocardiographic technique, ie, STE.
Study context
- Population
- Nondiabetic outpatients with heart failure with reduced ejection fraction (HFrEF) or HF with mildly reduced EF (heart failure with mildly reduced ejection fraction (HFmrEF))38% HFmrEF
- Participants
- 88 outpatients
- Comparison
- Dapagliflozin on top of optimal medical therapy (OMT) vs OMT
- Dapagliflozinn = 44
- OMTn = 44reference
- Primary endpoint
- Significant modification of LV global longitudinal strain, diastolic function (peak atrial longitudinal strain) and RV function by speckle tracking echocardiography
- Follow-up
- Baseline to 6 months
Methodological detailsprospective, single-centre, open-label
- Prospective
- Single-centre
- Open-label
Primary result
As reported in the abstract
Speckle tracking echocardiography parameters · 6 months
- All speckle tracking echocardiography (STE) values improved with dapagliflozin; nonsignificant improvement with OMT
- Dapagliflozin vs OMT: P < 0.0001
Original publication
Dapagliflozin Effects on Cardiac Deformation in Heart Failure and Secondary Clinical Outcome. JACC Cardiovasc Imaging. Published 17 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →